Pills of Genzyme Corp.'s chronic kidney disease treatment Hecterol, right, and Sanofi-Aventis SA's insomnia medicine Ambien are arranged for a photo at New London Pharmacy in New York. Photographer: JB Reed/Bloomberg
Pills of Genzyme Corp.'s chronic kidney disease treatment Hecterol, right, and Sanofi-Aventis SA's insomnia medicine Ambien are arranged for a photo at New London Pharmacy in New York. Photographer: JB Reed/Bloomberg
%7Cutmccn%3D(direct)%7Cutmcmd%3D(none);&utmn=190741312&utmp=%2Fphoto%2F2010-08-31%2Fsanofi-aventis-may-need-to-lift-genzyme-bid-to-77-a-share-citigroup-says&utmhn=10.248.179.17&utmac=UA-11413116-12&utmhid=330779061)